Skip to main content
. 2022 Apr 1;18(4):1063–1071. doi: 10.5664/jcsm.9804

Table 1.

Patient characteristics, comorbidities, sleep study parameters, and PAP adherence.

OSA (n = 36) OHS (n = 15) P
Demographics
 Age 48 ± 2.3 53 ± 3.2 ns
 Male, n (%) 15 (42) 4 (27) ns
 BMI (kg/m2) 50 (13) 58 (21) ns
 Ethnicity, n (%)
 Caucasian 23 (64) 8 (53) ns
 Pacific Islander 7 (19) 4 (27) ns
 Aboriginal 3 (8) 1 (6) ns
 Epworth sleepiness score 13 ± 6.0 14 ± 6.9 ns
 Never smoker, n (%) 20 (55) 4 (27) ns
 Pack-years 0 (13) 10 (20) ns
Comorbidities, n (%)
 Diabetes 15 (42) 9 (60) ns
 Hypertension 21 (58) 8 (53) ns
 Hypercholesterolemia 5 (14) 4 (27) ns
 Depression 4 (11) 4 (27) ns
 Stroke 1 (0.03) 0 (0) ns
 Coronary artery disease 5 (0.14) 1 (0.06) ns
Medications, n (%)
 ACE-inhibitor/ARB 18 (50) 6 (40) ns
 Beta-blocker 6 (17) 4 (27) ns
 Diuretic 7 (19) 1 (6) ns
 Aspirin or anticoagulant 6 (17) 6 (40) ns
 Cholesterol-lowering agent 12 (33) 6 (40) ns
 Oral hypoglycemic agent 16 (44) 6 (40) ns
Diagnostic sleep study parameters
 AHI (events/h) 71 ± 31.2 78 ± 47.4 ns
 Minimum SpO2 (%) 63 ± 18.8 48 ± 16.1 < .01
 TST with SpO2 < 90% (min) 140 ± 149.2 308 ± 139.6 < .01
 TST with SpO2 < 80% (min) 55 ± 19.9 112 ± 107.7 ns
 PAP compliance (minutes) 317.9 ± 92.9 375.1 ± 102.1 ns
 % Days with > 4 hours use 73 ± 26 80 ± 15.6 ns
Daytime PaCO2 (mm Hg)
 Visit 1 40 (7) 49 (6) < .01
 Visit 2 42 (4) 43 (6) ns
Daytime SpO2 (mm Hg)
 Visit 1 96 (2) 93 (5) < .01
 Visit 2 96 (2) 95 (1) < .01

Data are presented as mean ± standard deviation or median (interquartile range) unless otherwise stated. ACE = angiotensin-converting enzyme, AHI = apnea-hypopnea index, ARB = angiotensin receptor blocker, BMI = body mass index, ns = not significant, OHS = obesity hypoventilation syndrome, OSA = obstructive sleep apnea, PaCO2 = partial pressure of carbon dioxide, PAP = positive airway pressure, SpO2 = oxygen saturation by pulse oximetry, TST = total sleep time.